


AR/BRD4 RIPTAC-1

Chemical Properties

CAS No. :	3083307-42-7
Formula:	C50H54N10O5S
Molecular Weight:	907.09
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	AR/BRD4 RIPTAC-1 (Compound II-5) is an orally active Regulatory-inducible proximity-targeting chimera (RIPTAC). AR/BRD4 RIPTAC-1 induces the formation of a stable ternary complex between the androgen receptor (AR) and BRD4, thereby blocking BRD4 function. AR/BRD4 RIPTAC-1 inhibits the growth and proliferation of tumor cells. AR/BRD4 RIPTAC-1 holds promise for use in prostate cancer research. AR/BRD4 RIPTAC-1 is additionally applicable in molecular oncology research for investigating androgen receptor-epigenetic regulator interactions and for studying proximity-induced protein complex formation mechanisms in tumor-associated transcriptional regulation systems.
Targets(IC50)	Epigenetic Reader Domain,Androgen Receptor
In vitro	Methods: T47D cells were cultured in vitro and treated with AR/BRD4 RIPTAC-1 (Antiproliferative agent-71) for 72 hours, then the half-maximal growth inhibitory concentration GI ₅₀ was determined. Results: AR/BRD4 RIPTAC-1 (Antiproliferative agent-71) inhibited the growth of T47D cells with a GI ₅₀ lower than 0.5 μM [1].
In vivo	Methods: CB17.SCID mice bearing VCaP tumors were orally administrated for 7 consecutive days, and tumor growth was monitored. Results: AR/BRD4 RIPTAC-1 (Antiproliferative agent-71) effectively inhibited tumor proliferation in vivo [1].

Solubility Information

Solubility	DMSO: 40 mg/mL (44.1 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1024 mL	5.5121 mL	11.0243 mL
5 mM	0.2205 mL	1.1024 mL	2.2049 mL
10 mM	0.1102 mL	0.5512 mL	1.1024 mL
50 mM	0.022 mL	0.1102 mL	0.2205 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kyle J. Eastman, et al. Heterobifunctional compounds and methods of treating disease. WO2025085738A1. 2025-04-24.

Raina K, et al. Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively. bioRxiv. 2023 Jan 2:2023.01.01.522436.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481